Lukaszuk Krzysztof, Podolak Amira, Jakiel Grzegorz, Kiewisz Jolanta, Woclawek-Potocka Izabela, Lukaszuk Aron, Rabalski Lukasz
Invicta Research and Development Center, 81-740 Sopot, Poland.
Department of Obstetrics and Gynecology Nursing, Medical University of Gdansk, 80-210 Gdansk, Poland.
Vaccines (Basel). 2021 Nov 4;9(11):1277. doi: 10.3390/vaccines9111277.
In the context of the ongoing COVID-19 pandemic, using a half-dose schedule vaccination can help to return to normalcy in a cost-efficient manner, which is especially important for low and middle-income countries. We undertook a study to confirm that in adults up to 55 years old, the humoral response to the half-dose (15 µg, 35 participants between 18 and 55 years old) and to the recommended dose (30 µg, 155 participants) in the two-dose three-week interval schedule would be comparable. Antibody levels were measured by the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, upper detection limit: 2570 BAU/mL) on the day of dose 2 of the vaccine and then 8-10 days later to assess peak response to dose 2. The difference in proportions between the participants who did and did not exceed the upper detection limit 8-10 days after dose 2 was not statistically significant ( = 0.152). We suggest that a half-dose schedule can help to achieve widespread vaccination coverage more quickly and cheaply.
在当前新冠疫情背景下，采用半剂量接种方案有助于以经济高效的方式恢复正常状态，这对低收入和中等收入国家尤为重要。我们开展了一项研究，以确认在55岁及以下成年人中，两剂间隔三周接种方案下，半剂量（15微克，18至55岁的35名参与者）和推荐剂量（30微克，155名参与者）的体液免疫反应是否相当。在接种疫苗第二剂当天，然后在8至10天后，通过Elecsys抗SARS-CoV-2 S检测法（罗氏诊断公司，检测上限：2570 BAU/mL）测量抗体水平，以评估对第二剂的峰值反应。接种第二剂8至10天后，超过和未超过检测上限的参与者比例差异无统计学意义（ = 0.152）。我们建议，半剂量接种方案有助于更快、更经济地实现广泛的疫苗接种覆盖。
